| Trial ID: | L2901 |
| Source ID: | NCT01515592
|
| Associated Drug: |
Liraglutide
|
| Title: |
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide|DRUG: liraglutide|DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: Adverse events|Body weight|Antibody against liraglutide | Secondary: Area under the plasma liraglutide concentration curve|Cmax, maximum concentration|tmax, time to reach Cmax|Terminal elimination rate constant|t½, terminal elimination half-life|24-hour profiles of plasma glucose|24-hour profiles of serum insulin
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-01
|
| Completion Date: |
2006-04
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-25
|
| Locations: |
Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01515592
|
